Revolymer plc announced that its Chairman of the Board of Directors, Mr. John "Jack" Keenan, has retired from this role. After an externally led search process, Dr. Bryan Dobson, an existing independent non-executive director of Revolymer since 2012, has accepted the role of Chairman, succeeding Mr. Keenan with immediate effect. Mr. Keenan will remain on the Board as an independent non-executive director to provide continuity until a replacement is recruited.

Mr. Keenan has been a non-executive director of the business since January 2008, and Chairman since the flotation on the AIM Market in July 2012. He has played a significant role throughout this period, applying his considerable experience to guiding the commercial development of the business as well providing advice on corporate governance. Dr. Dobson has extensive expertise in the specialty chemicals industry which is highly relevant to Revolymer's business plan.

Specifically, he has nearly 40 years' experience in the chemicals industry, including with ICI plc and Croda International plc. He was a member of the executive management teams in Croda and in a number of large specialty chemicals businesses in ICI, and has extensive management experience running regional and global business units in the UK, US, Belgium and The Netherlands. He also has expertise in developing new business in specialty chemicals sectors; extensive functional experience in R&D and operations and significant M&A experience.

Dr. Dobson is currently Chairman of Applied Graphene Materials plc and a non-executive director of the Newcastle upon Tyne Hospitals NHS Foundation Trust.